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biomarkers for serous and papillary serous
ovarian cancer subtypes
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Anil Sood3, Wei Hu3, Ruzeen Patwa1, Patrick Blake4, Polina Chirina1, Jin Oh Jeong1, Heejin Lim1, Andre Goy1,
Andrew Pecora1 and K Stephen Suh1*

Abstract
Background: Early detection of ovarian cancer remains a challenge due to widespread metastases and a lack of
biomarkers for early-stage disease. This study was conducted to identify relevant biomarkers for both laparoscopic
and serum diagnostics in ovarian cancer.
Methods: Bioinformatics analysis and expression screening in ovarian cancer cell lines were employed. Selected
biomarkers were further validated in bio-specimens of diverse cancer types and ovarian cancer subtypes. For
non-invasive detection, biomarker proteins were evaluated in serum samples from ovarian cancer patients.
Results: Two kallikrein (KLK) serine protease family members (KLK6 and KLK7) were found to be significantly
overexpressed relative to normal controls in most of the ovarian cancer cell lines examined. Overexpression of
KLK6 and KLK7 mRNA was specific to ovarian cancer, in particular to serous and papillary serous subtypes. In situ
hybridization and histopathology further confirmed significantly elevated levels of KLK6 and KLK7 mRNA and
proteins in tissue epithelium and a lack of expression in neighboring stroma. Lastly, KLK6 and KLK7 protein
levels were significantly elevated in serum samples from serous and papillary serous subtypes in the early stages
of ovarian cancer, and therefore could potentially decrease the high “false negative” rates found in the same patients
with the common ovarian cancer biomarkers human epididymis protein 4 (HE4) and cancer antigen 125 (CA-125).
Conclusion: KLK6 and KLK7 mRNA and protein overexpression is directly associated with early-stage ovarian tumors
and can be measured in patient tissue and serum samples. Assays based on KLK6 and KLK7 expression may provide
specific and sensitive information for early detection of ovarian cancer.
Keywords: Biomarker, Ovarian cancer, Diagnostic, Early detection, Bioinformatics

Introduction
Ovarian cancer (OVC) ranks as the fifth most common
cancer in women and has the highest mortality rate among
gynecologic malignancies [1,2]. Although the 5-year survival rate of OVC is around 90% when detected in its early
stages (I/II), nearly 80% of new cases are diagnosed in
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advanced stages (III/IV) because of the asymptomatic nature of the disease. Unfortunately, the 5-year survival rate
of advanced OVC is as low as 11% [3].
Identification of early detection biomarkers for ovarian
carcinoma remains a challenge due to a wide range of
morphological, clinical and genetic variations found in
OVC progression [4]. Currently available biomarkers lack
specificity and sensitivity that are required for routine
clinical use [5]. The only clinically validated biomarker
used for early detection, disease monitoring, and assessing
relapse or response to treatment is cancer antigen 125
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(CA-125 or MUC-16). Although CA-125 serum expression is elevated above normal levels in early stage (23%)
and late stage (80%) disease, this antigen lacks specificity
and sensitivity for use as a single marker for early OVC
detection [6,7]. In addition, CA-125 overexpression is frequently observed in benign conditions (e.g., endometriosis) and thus it lacks accurate diagnostic value for early
stage disease [8]. As an early detection biomarker of OVC,
recent reports suggested that the WAP four-disulfide core
domain 2 (WFDC2 or HE4) protein could provide greater
sensitivity and specificity than CA-125 [9,10]. An assay
that detects a combination of HE4, CA-125, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and vascular cell adhesion molecule 1 (VCAM1)
expression in serum has demonstrated significantly better
sensitivity for early stage OVC detection compared to benign tumors [11,12]. In addition, the Food and Drug Administration (FDA) has approved the OVA1 test, which
consists of a panel of five biomarkers: transthyretin, apolipoprotein A-1, beta2-microglobulin, transferrin and CA125 [13]. Slightly after the approval of the OVA1 test, the
FDA approved the use of the Risk of Ovarian Malignancy
Algorithm (ROMA) that involves CA-125 and HE4
measurements and a definition of menopausal status
[14]. These tests suggest that use of a combination of
multiple markers can generate synergistic advantages
over single marker diagnostics [15].
A number of human kallikrein-related peptidase (hKLK)
family members have been associated with human cancers
and exhibit differential expression in many types of advanced cancers, including gastrointestinal, head and
neck, lung, ovarian and brain [16-18]. However, to date
few reports have focused on detection of early stage
OVC using KLK markers, or more specifically, by measuring levels of kallikrein-related peptidase 6 (KLK6) and
kallikrein-related peptidase 7 (KLK7). In a study by El
Sherbini et al., 40% of stage I/II ovarian cancer patients
(n = 10-15) presented above normal levels of KLK6
while 83.3% of stage III/IV patients (n = 12) were KLK6 positive [19]. The hKLK family is comprised of 15 homologous
secreted trypsin- or chymotrypsin-like serine proteases,
encoded by tightly clustered genes found in the chromosome
19q13.4 region [20]. hKLK transcription is regulated by
many stimulatory and inhibitory factors, including steroid
hormones [21]. hKLKs are co-expressed in the epithelia of
several organs and mediate a range of physiological functions, including skin desquamation and body fluid homeostasis [22]. A number of studies have found that hKLK
genes/proteins are aberrantly expressed in multiple human cancers, and their overexpression in late stage tumors
is often associated with unfavorable patient prognosis
[23-25]. hKLKs are associated with cancer cell growth,
angiogenesis, invasion and metastasis through their proteolysis of signaling proteins and extracellular matrix components
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[26], and in a recent study hKLKs were associated with
elevated TGFβ signaling in ovarian cancer cells [27].
While elevated hKLK expression has been reported in
late stage OVC [28,29], its expression or role in early
disease stages has not been extensively studied.
In this study, we aimed to identify early detection biomarkers for OVC by using a multistep screening method
of bioinformatics-guided selection and subsequent expression screening in relevant cell lines, followed by expression validation in patient samples. We were able to
identify at least two biomarkers, KLK6 and KLK7, by
this strategy and characterized their potential for detecting early stage OVCs. We then compared the levels of
these proteins in early stage OVC patients to levels of
proteins commonly used for OVC detection, including
CA-125 and HE4.

Materials and methods
Bioinformatics

The Biomax BioXM™ Knowledge Management System
(Biomax Informatics AG, Munich, Germany) was used
to mine and generate a rank list of candidate OVC genes
from the 6,955 manually curated cancer genes of the
National Cancer Institute (NCI) and the Cancer Gene
Index (CGI). The Biomax BioLT ™ Tool (NLP) was used
to mine 18 million Medline abstracts (94 million sentences) to find and validate genes associated with cancer
terms, gene-disease relationships and gene-compound/
treatment relationships for each of the 6,955 cancer genes.
The NCI Thesaurus Role Codes and Karp’s Evidence
Codes [30] were used to annotate over 1.3 million related
sentences. The search for potential biomarkers was
performed by initiating queries on BioXM with a combination of search terms, including ovarian, cancer, biomarker,
over-expression and up-regulation or down-regulation.
Cell culture

OVC cell lines TOV21G, TOV112D, OV-90, CAOV3,
SKOV3, PA-1, SW626, and ES-2 [31-38] were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA) and cultured in the media suggested by
the distributor. SKOV-1, IGROV-1, HEY, OV-2008, A2780,
UCI-101 and UCI-107 cells [39-45] were obtained from
Drs. Howell (University of California, San Diego) and
Carpenter (University of California, Irvine), and were
all cultured in RPMI 1640 medium (Invitrogen, Carlsbad,
CA). The DOV13 cell line [46] was obtained from Dr. Bast
(MD Anderson Cancer Center) and cultured in DMEM.
The CSOC882 cells [47] were obtained from Dr. Karlan
(University of California, Los Angeles) and cultured in
McCoy’s 5A medium. Cell line 2774 [48] was obtained
from Dr. Wolf (MD Anderson Cancer Center) and cultured in EMEM. The BG-1 cell line [49] was obtained
from Dr. Korach (NIEHS, National Institutes of Health)
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and cultured in a 1:1 mixture of DMEM and F12 media
without phenol red. The normal ovarian epithelial cell lines
FHIOSE118 and IOSE523 [50,51] were obtained from
Dr. Cheng (Moffitt Cancer Center) and Dr. Nelly Auersperg
(University of British Columbia), respectively, and cultured
in a 1:1 mixture of MCDB105 and Medium 199. All culture
media were supplemented with 5-15% v/v fetal bovine serum
(FBS; Hyclone, Logan, UT) and penicillin/streptomycin solution (Invitrogen). A detailed list of all ovarian cells lines used
in this study is provided in Additional file 1.
RT-PCR and statistical analysis

Total RNA was extracted from cells using Trizol
(Invitrogen), and cDNA was generated with the SuperScript
III RTS First-Strand cDNA Synthesis Kit (Invitrogen) as described by the manufacturer. All amplification primers were
synthesized for use with the ABI7900 RT-PCR device
(Applied Biosystems, Foster City, CA) as recommended
by Applied Biosystems, and they were demonstrated to
produce a single PCR band of the expected size by agarose
gel electrophoresis of end-point PCR products from
cDNA templates generated from normal ovarian cell
lines. All qPCR assays used MicroAmp Fast Optical
96-Well Reaction Plates with Barcode (Applied Biosystems)
in the standard mode (first denaturation at 95°C for
10 minutes, and then 40 cycles at 95°C for 15 seconds
followed by 60°C for 1 minute). The qPCR data were
normalized against internal GAPDH or β-actin cDNA
and then analyzed by software provided with the ABI7900.
Poor quality specimens that produced no meaningful
values after 40 cycles of qPCR were not included in the
data processing steps. The TissueScan Cancer Survey
Panel and OVC Panel I-IV (both from OriGene, Rockville,
MD) were used as described by the manufacturer. All cancer tissues in these panels contain an average of 75% cancer
cells and 25% surrounding stroma. Ovarian tissue samples
were also obtained from tissue banks at the MD Anderson
Cancer Center (MDACC) and Thomas Jefferson University
(TJU), which were both IRB-approved. All qRT-PCR assays
were done in duplicate, and experiments were repeated
a minimum of two times. For statistical analysis, SigmaPlot 12.5 (SysStat Software, Chicago, IL) or JMP4 (SAS
Institute) software was used to determine p values of
differences in expression between ovarian and other
cancer types versus corresponding normal tissues. A t-test
or analysis of variance (ANOVA) was used to calculate
differences between means of sample groups versus normal controls and derive the corresponding p values.
Immunohistochemistry

Whole-mount paraffin-embedded tissues and tissue arrays (US Biomax, Rockville, MD; Proteogenex, Culver
City, CA; and the Tissue Bank of Thomas Jefferson
University, IRB-approved) were subjected to histochemical

Page 3 of 15

staining as described by the antibody manufacturers.
Diaminobenzidine (DAB) staining was visualized by brightfield microscopy. The slides were photographed with
an Axio Imager Microscope (Carl Zeiss, Thornwood, NY),
and images were taken at 20× and 40× magnification.
In situ hybridization

Ovarian tissue sections were de-paraffinized, processed
for high pH antigen retrieval, de-proteinated by proteinase K treatment (10 μg/ml) (Roche) in a 37°C water bath
for 20 minutes and then treated with 0.2% w/v glycine
for 30 seconds to inactivate the enzyme. After fixing the
sections with 4% w/v paraformaldehyde (PFA; Electron Microscopy Sciences, Fort Washington, PA) for 10 minutes,
the sections were blocked with hybridization buffer (50% v/v
formamide, 5× saline-sodium citrate (SSC), 9.2 mM citric
acid, 50 μg/ml heparin, 500 μg/ml yeast RNA, and 0.1% v/v
Tween-20) for 2 hours at 54°C. The sections were incubated overnight in a humidified chamber with digoxigenin
(DIG)-labeled probes (20 nM, Exiqon, Woburn, MA). The
sequence of the KLK6 [GenBANK: NM_001012964]
probe was 5′-DIG-GACCAAGTCCTCACTCATCAC-3′,
and for KLK7 [GenBANK: NM_139277] the probe was
5′-DIG-AAAGTACACAGAAGGAAGGAGA-3′. The sections were washed for 30 minutes three times with
hybridization washing solution (50% v/v formamide
containing 2× SSC) at 54°C and then five times for five
minutes each with washing solution (0.1% v/v Tween-20
in phosphate-buffered saline, PBS) at room temperature.
After blocking for 3 hours at room temperature with
5% w/v bovine serum albumin (BSA), the sections were
treated with mouse anti-DIG antibody (SC-57583, Santa
Cruz Biotechnology, Santa Cruz, CA) at a dilution of
1:1000 in 5% BSA overnight. The sections were washed
four times for five minutes each in PBS containing 0.1% v/v
Tween-20, and then once in PBS for 5 minutes. To
visualize bound probe, the Envision G/2 System/AP
Rabbit/Mouse Permanent Red kit (Dako, Carpinteria,
CA) was used as described by the manufacturer. The
stained tissues were further processed and photographed
as described above for immunohistochemistry.
Immunoblot analysis

Serum samples from OVC patients (n = 44) and normal female donors (n = 10) were purchased from Proteogenex
(Culver City, CA) and Bioserve (Beltsville, MD). The samples
represented diverse tumor stages, age groups and races.
100 μl of serum was used as starting material from all samples and abundant serum proteins were depleted with ProteoPrep Blue Albumin and IgG Depletion Kit (both from
Sigma-Aldrich, St. Louis, MO) as described by the manufacturer prior to SDS-PAGE. Twenty micrograms of proteins
from eluates in loading buffer (0.5 M Tris–HCl, 0.15 M
NaCl, 1% IGEPAL, complete mini [Roche Applied Science,
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Indianapolis, IN] containing 10 μg/ml leupeptin, 10 μg/ml
aprotinin, 1 mM p-methylsulfonylfluoride [PMSF], 1 mM
NaVO3, 0.05 M NaF, and 1 mM EGTA) were resolved by
SDS-PAGE in 12.5% w/v gels and then further examined by
western blot analysis. The membranes were probed with primary anti-KLK6 (H60) and -KLK7 (1407) antibodies (Santa
Cruz Biotechnology) and then with appropriate horse radish
peroxidase (HRP)-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories, West Grove, PA). The reactive proteins were visualized by chemiluminescence with
SuperSignal West Dura substrate (Thermo Fisher Scientific,
Rockford, IL).
Enzyme-Linked Immuno-Sorbent Assay (ELISA)

ELISA kits (R&D Systems, Minneapolis, MN) for measuring the presence of CA-125 and HE4 in corresponding
OVC patient serum (Proteogenix, Culver City, CA) were
used for this study and the manufacturer’s protocol was
followed. Recombinant human CA-125 (R&D Systems,
Minneapolis, MN) or HE4 (Novoprotein, Summit, NJ)
were used as positive controls and further diluted as standards. Nineteen serum samples of early stage patients were
evaluated for this purpose: Stage I (7 patients) and stage II
(12 patients), and the same proteins were compared in two
stage III and two stage IV patients. Levels of these proteins
were also measured in serum from three healthy individuals. Serum was diluted (1:4) before the measurements and
the results were calculated as averages of triplicates of each
serum sample. The colorimetric results were read at
495 nm on a BioTek Synergy HT reader and Gene5
software was used to read and analyze the results.
A detailed description of the samples used (including
numbers, sources and suppliers) as related to the assays
performed is provided in Additional file 2.

Results and discussion
Pre-screening of potential OVC biomarkers using
bioinformatics tools and an OVC cell line library

To pre-screen human genes that have a high potential
for use as early detection biomarkers, the BioXM bioinformatics platform was used with query strings including ovarian, biomarker, up-regulation, down-regulation
and over-expression. The output data set contained a qualified list of 117 genes (Table 1) that represent diverse
processes, including apoptosis, proliferation, invasion,
metabolism, and angiogenesis. For mRNA expression
screening, a library of 19 OVC and two normal ovarian
cell lines was used. The phenotype of normal ovarian
cell lines was a mixture of epithelial and fibroblastic
(data not shown). Initially, all 117 genes were tested in
seven OVC cell lines representing different disease grades
and subtypes as well as in two normal ovarian cell lines by
qRT-PCR (Figure 1A). In the majority of these cell lines,
mRNAs of the clinically established OVC biomarkers
CA-125, HE4 and CEA were overexpressed. From the
first stage of screening, 30 candidate genes were selected
that are differentially expressed in cancer versus control
cell lines: APOD, BCHE, BCL-2, CA-125, CDX2, CLDN3,
CLDN4, CSF1, DAB2, DUSP1, ETS1, IGFBP5, IL13RA2,
JUP, KLK5, KLK6, KLK7, KLK8, KLK13, MAGEA4, MASPIN, MIF, MLANA, MSLN, P11, PRSS8, ST14, TNFRSF1B,
VEGFC, and WFDC2. Of these, 12 genes were consistently either up- or down-regulated by more than 10-fold
in over 70% of all OVC cell lines that represent different
grades, but were mostly derived from late-stage OVC
with BCL-2, CDX2, KLK7, KLK6, P11 and PRSS8 genes
up-regulated, and IGFBP5, DUSP1, DAB2, VEGFC, IL13RA2
and APOD genes down-regulated. Among these 12 genes,
KLK6 and KLK7 were consistently up-regulated in the

Table 1 Bioinformatics-based data mining method for the identification of potential ovarian cancer biomarkers
Potential biomarkers for ovarian cancer
ATP7B

CA125

CLEC3B

KLK6

TOP2A

ARID4B

CEA

ID2

IGFBP2

INHA

PDGFA

HE4

DUSP1

BSG

CLDN3

REEP5

MIF

IGF2BP1

LGALS3BP

CDC25C

BRCA2

CA72-4

IL13RA2

STAT3

CLDN4

CCT3

AFP

IQGAP1

MSLN

NME1

DNAJC15

BARD 1

PLK1

RAET1E

COPS5

CD47

Prolactin

RHOC

ST14

AKT2

KLK14

BCL2

VIL2

TITF1

CSF1

ETV4

MUC 1

RNASE2

AMH

ANGPT2

KLK9

IGFII

APOD

TFF1

EFNB1

MAGEA4

AMH

SYCP1

CDC25A

XIST

WFDC2

BAG1

CD247

SPINK1

KLK11

SCGB2A1

WT 1

TRIM25

CSF1R

KLK10

ERCC1

BAG3

CDC25B

PRSS8

KLK13

SIX5

OGP

P11

GADD45A

KLK15

KLK8

BAG 4

DAB2

CCNE1

MVP

ZNF217

CDX2

CYP2A

HLA-G

KLK5

RBL2

Osteopontn

HMGA1

CEACAM6

PARP1

EYA2

SMRP

PTK2

JUP

KLK7

SKP2

Maspin

HOXB7

ETS1

VEGFC

ELF1

Bcl-XL

TACC3

MLANA

SOD2

IGFBP5

MSN

BCHE

EPHA2

ASNS

MUC5AC

TNFRSF1B

BioXM software was used to mine the Cancer Gene Index (CGI) to identify genes that are differentially regulated in OVC. This bioinformatics-guided approach
identified 117 genes that are supported by experimental evidence in the published literature. Genes are categorized based on signaling pathways and 12 genes
showing robust differential expression in the majority of the 21 OVC cell lines versus normal ovarian cell lines (all with p <0.05) are highlighted in bold text.
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Figure 1 Overexpression of KLK6 and KLK7 genes was observes in OVC cell lines. (A) Established OVC cell lines representing different ages,
stages and subtypes were selected and tested by end-point PCR for expression of known OVC genes (CA-125, HE4, and CEA) relative to normal
ovarian epithelial cell lines. Amplified cDNAs were qualitatively compared following electrophoretic separation as ethidium bromide-stained bands
on agarose gels. (B) Gene expression of KLK6 and KLK7 in OVC cell lines (solid black bars) and normal ovary cell lines (N) was analyzed by qRT-PCR
and normalized against a “primary-like” normal ovarian cell line (IOSE523; solid gray bar). IOSE523 cells begin to senesce after twenty passages while
FIOSE118 cells are immortal. The mean fold change represents triplicate measurements, and standard error bars are shown.

majority of cell lines in the OVC cell line library, which
was originally created for mRNA expression screening
(Figure 1B). A flowchart of the OVC biomarker prescreening process is provided in Additional file 3.
Elevated expression of KLK6 and KLK7 mRNA was
detected in OVC specimens

Expression of the 12 selected genes was analyzed by
qRT-PCR as a final screening step, with measurements
taken in normal and cancer samples from 394 individuals
that represented 18 different tumor types apart from
OVC. The analysis indicated that the mean differential
mRNA expression between ovarian tumor versus normal
ovarian tissues was over 500-fold for KLK6 (p <0.001) and
over 3,000-fold for KLK7 (p <0.001, as indicated by an asterisk). The normal control used here was a mixture of
epithelial and stromal components, which represents the
true normal ovary. In addition, the differential overexpression of both mRNAs was highly specific to OVC relative
to “cancer versus corresponding normal tissues” of other
cancer types (p <0.001 at 95% confidence level, CI = 20
with 30% of total population) (Figure 2). Moreover, the

difference between cancer versus corresponding normal
tissue was the greatest in ovarian cancer compared to
other major cancer types. In contrast, the mRNA expression levels of KLK6 and KLK7 were down-regulated in
breast (87-fold and 75-fold, respectively) and kidney cancers (68-fold and 234-fold, respectively) relative to corresponding normal tissues.
Expression of KLK6 and KLK7 in different subtypes, grades
and stages of OVC

The gene expression patterns of KLK6 and KLK7 in
OVCs were analyzed by qRT-PCR in 192 cDNA samples
derived from normal (n = 27) and OVC (n = 135 and 142
for KLK6 and KLK7, respectively) tissues representing
eight major subtypes of epithelial origin, including papillary serous, serous, endometrioid, mucinous, clear cell,
primary metastatic carcinoma and borderline cases. First,
subtype-dependent expression of hKLKs was evaluated.
Both KLK6 and KLK7 were significantly overexpressed
(p <0.005) in papillary serous, serous, metastatic carcinoma, borderline and mixed type carcinomas versus
normal ovary tissues (Figure 3A). In mucinous and clear
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Figure 2 Differential expression of KLK6 and KLK7 genes is significantly selective for OVC versus 18 other human cancer types.
Over 390 cDNAs derived from 19 different cancer tissues and corresponding normal tissues were assayed by RT-qPCR to quantitatively measure
KLK6 (A) and KLK7 (B) gene expression. The fold change represents the level of gene expression in cancer normalized against the corresponding
normal tissue. The mean number of samples used in the assay was 15 for cancer and five for corresponding normal tissues. The statistical significance
of differential KLK6 and KLK7 expression in OVC (solid black bar) over other cancer types (solid gray bars) was determined to be p <0.001 (indicated by *)
by one-way ANOVA (SigmaStat). Abbreviations for cancer types are Ov = ovarian, AG = Adrenal Gland, Br = Breast, CV = Cervix, Co = Colon, En = Uterine
Endometrium, Kd = Kidney, Es = Esophagus, Lv = Liver, Lu = Lung, LN = Lymph Node, LT = Lymphoid Tissue, Pn = Pancreas, Pr = Prostate, St = Stomach,
Te = Testis, TG = Thyroid Gland, UB = Urinary Bladder, and Ut = Uterus.

cell OVC subtypes, both genes, but especially KLK6, were
also overexpressed (p <0.01), albeit to a lesser extent compared to the other subtypes. Thus, this overexpression signature was found in subtypes that occur in more than
90% of OVCs, which indicates that KLK6 and KLK7 are
potential candidates for early detection markers. Next, we
evaluated grade-dependent expression and found that KLK6
and KLK7 transcripts were overexpressed by 84- and 212fold, respectively, in low-grade (G1) tumors versus normal
controls (p <0.001), and expression of both increased >3fold from lower (G1) to higher (G3) tumor grades or borderline (GB) tumors (Figure 3B). For tumor staging, both KLK6
and KLK7 mRNA levels were elevated 76-fold and 331-fold,
respectively, in stage I versus normal controls (p <0.001)
(Figure 3C). The expression of KLK6 and KLK7 was not statistically significant (p >0.05) between higher grades and
stages. These elevated mRNA levels were maintained in
advanced tumor grades and stages. Together, these data

suggest that KLK6 and KLK7 may be very useful as biomarkers for detection of low-grade and early stage OVCs.
Overexpression and specificity of KLK6 and KLK7 in tumor
epithelia

The overexpression and localization of KLK6 and KLK7
were verified by histologic analysis of 512 samples from
normal ovary and ovarian tumors, using hybridization of
customized oligonucleotide probes for each gene in situ
in either whole mount or tissue arrays. While KLK6 and
KLK7 transcripts were expressed at a basal level in normal ovaries, the expression of these two genes increased
significantly in tumors versus controls, and their expression was limited exclusively to the epithelium compartment
of all ovarian tumors analyzed (Figure 4A). Meanwhile,
neighboring tumor stroma, regardless of subtype, was negative for expression in all cases analyzed. Moderate differences in staining intensities were observed between low
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Figure 3 KLK6 and KLK7 gene expression is subtype-specific (A) and increases progressively in advanced stages (B) and higher grades
(C) of ovarian tumors. Gene expression levels quantitatively measured by qRT-PCR in cDNAs derived from ovarian tumors versus normal ovarian
tissue. The fold change level is represented by the height of each histogram and the fold change is indicated in white boldface within the back
bars for each subtype (error bars are indicated). Abbreviations for OVC subtypes in (A) are PS = Papillary Serous, S = Serous, E = Endometrioid,
M = Mucinous, C = Clear Cell, MC = Metastatic Carcinoma (adenocarcinoma of the ovary, metastatic), B = Borderline and MT = Mixed Type.
Abbreviations used in (B) are G1, G2, and G3, which represent progressive tumor grades; GB is the grade corresponding to borderline subtypes. In
(C), the four progressive tumors stages are denoted as I, II, III, and IV. The number of ovarian tumor samples analyzed is given in parentheses.
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C

Figure 4 KLK6 and KLK7 genes and proteins are overexpressed in epithelia but absent in stroma of ovarian tumors. (A) To detect
mRNA in tissues, serous ovarian tumors (S) and normal tissues (N) were hybridized in situ with KLK6 and KLK7 oligonucleotide probes followed by
visualization of red chromogen staining by bright field microscopy under 10 × magnification. (B) To detect KLK6 and KLK7 protein expression in
tissues, subtypes of ovarian tumors (S = Serous, PS = Papillary Serous, E = Endometrioid) and normal ovary tissues (N) either in whole mount
sections or tissue arrays were analyzed with IHC. DAB staining was visualized by brightfield microscopy. (C) Detection of KLK6 and KLK7 protein
levels in serous carcinomas by immunohistochemistry, observed under 40 × magnification that allows visualization of nuclear staining, which is
indicated by a solid arrow. Cytoplasmic staining is indicated by a dotted arrow.

versus high grade, and early versus late stages of ovarian tumors (data not shown). Immunohistochemical analysis of
KLK6 and KLK7 on the same set of tissues demonstrated
that protein expression patterns of the KLKs were identical
to those seen with in situ hybridization (Figure 4B). Both
proteins are expressed exclusively in tumor epithelium of
serous, endometrioid and papillary serous cancers, whereas
the neighboring stroma was minimally positive in all subtypes of ovarian tumors tested (Figure 4B). The KLK7 protein had a predominantly cytoplasmic localization in serous

subtypes of OVC cells, while KLK6 showed both cytoplasmic and nuclear staining (Figure 4C).
The levels of KLK6 and KLK7 mRNA and proteins are
elevated in tissue and sera from early stage papillary
serous and serous OVC patients

Elevated KLK expression during the early stages of serous
and papillary serous ovarian carcinomas, which comprise
the most frequently diagnosed ovarian tumors, was found
in an analysis of 59 early stage OVC samples obtained
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from the TJU and MDACC tissue archives. Our data consistently support that KLK6 and KLK7 mRNA expression
is elevated in all tumor stages of serous and papillary serous carcinomas relative to normal ovarian epithelial tissues
(Figure 5A). Transcripts were over-expressed by nearly
200- to more than 300-fold in stage I or II carcinomas versus normal ovarian tissues (p <0.001 for both KLK6 and
KLK7), indicating their utility as excellent biomarkers for
early detection of serous and papillary serous subtypes in
biopsy samples. In these ovarian tumor subtypes, KLK7
expression, but not that of KLK6, continued to increase
in stage III and state IV. Since KLK family members are
secreted proteins [52], we further investigated the protein
levels by immune-blot analysis of sera obtained from
OVC patients. Serum samples were pre-cleared to deplete
the most abundant serum proteins (see Materials and
methods), and KLK6 and KLK7 did not bind to serum
proteins that bound to the pre-clearing column (data not
shown). In these pre-cleared samples, KLK6 and KLK7
protein expression was significantly elevated in stage I
serous and papillary serous OVC when compared with
pooled normal serum (Figure 5B). Other subtypes (no asterisk, and subtypes not indicated) showed mixed expression
levels in the serum samples from early stage tumors. Densitometry analysis of serous OVC and these two subtypes in
stage I versus pooled normal serum showed a mean foldincrease of 22-fold for KLK6 and 6.7-fold for KLK7 (p <0.01,
Figure 5B), suggesting that both proteins may be useful as
early detection biomarkers in serum samples.
KLK6 and KLK7 can complement established OVC markers
HE4 and CA-125 for early detection of ovarian cancer

The most common criteria that clinicians have been
using to detect OVC are CA-125 levels, pelvic examination, presence of ascites and family history. Due to the
limitations of CA-125 for early detection of OVC, the
addition of HE4 as an early detection biomarker improved overall sensitivity, but this combination may still
be insufficient for detecting different OVC subtypes.
ELISA assays to detect those proteins in our early stage
OVC patients (Figure 6) demonstrated that CA-125
was detected at above normal levels in only 7 out of 19
early stage patients and in 3 out of 4 advanced stage
(stages IIIC and IV) patients, with the highest overall
levels seen in stage IV patients. HE4 was found in 11 out
of 19 early stage patients and in 3 out of 4 advanced stage
patients where the highest levels were detected in one
stage IIA patient, in three stage II patients and in one
stage IV patient. These results indicate that for early stage
patients (Stages I and II) the sensitivity (or true positive
rate) for CA-125 was only 0.61, and 0.7 for HE4. In
addition, we defined a group of seven “false-negative” patients for both CA-125 and HE4. This category included
4, 2 and 1 patient with stage I, stage II and stage III
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disease, respectively. When the same patient population was analyzed for KLK6 and KLK7 expression by
immune-blotting, both proteins were found to be significantly up-regulated, particularly in Stage I serous
and papillary serous ovarian carcinoma (Figure 5B). In
addition, our preliminary KLK7 serum ELISA data indicate that levels of this protein in OVC patients are
significantly higher compared to its levels in normal
individuals (p <0.05), and there is no significant difference
in serum KLK7 levels between benign and normal individuals (P >0.05). An additional figure file demonstrates this
in more details (see Additional file 4). Comparison of
KLK7 levels between the OVC (n = 17) and the benign
(n = 19) groups provided a sensitivity of 62.5% (95%
confidence interval [CI] 35.4%-84.8%) and specificity
of 94.4% (95% confidence interval [CI] 72.7%-99.9%).
When KLK7 levels were compared between the OVC
and the normal group (n = 19), sensitivity was calculated
as 62.5% (95% confidence interval [CI] 35.4%-84.8%) and
specificity calculated as 100% (95% confidence interval
[CI] 81.4%-100%). When using area under the receiver
operator characteristic curves (AUC ROC) to evaluate
KLK7 as a potential biomarker, AUC value was 0.83
(95% confidence interval [CI] 0.69-0.97) when comparing the OVC group to the normal group and 0.73 (95%
confidence interval [CI] 0.55-0.91), when comparing
the OVC group to the benign group. AUC values can
be in the range 0.5 (for a non-informative biomarker) to 1
(for a perfect biomarker). Similarly to our findings, Shan
et al. reported that tissue KLK6 concentrations were significantly elevated in the OVC group (N = 259) compared
to levels in benign (N = 49) and normal (N = 34) groups
(P <0.001). No significant difference in KLK6 concentrations was detected between the benign and the normal
groups [53]. These data indicate that KLK6 and KLK7
can be very selective biomarkers for early detection of
the most common types of OVC, and may efficiently
complement CA-125 and HE4 as early detection tumor
biomarkers.
Our approach of querying the CGI to identify potential
biomarkers for OVC with BioXM software resulted in
several candidates for further tests. This cancer gene
database, which is manually curated and was originally
derived from clinicopathology-based projects (i.e., tumor
staging), is in many cases an excellent source of clinically
relevant biomarkers for diagnostic use, especially for
early cancer detection. Expression pre-screening in OVC
cell lines was a practical solution for obtaining broad expression profiles and conserving invaluable patient samples. Systematic expression screening identified robust
KLK6 and KLK7 mRNA overexpression in the majority
of the OVC cell lines tested, and this may be related to
up-regulation in response to high levels of steroid hormones in these cells [54]. Despite robust KLK mRNA
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Figure 5 KLK6 and KLK7 mRNA and protein levels significantly increase in tissue and serum samples from early stage serous carcinomas.
(A) Gene expression of KLK6 (solid black bar) and KLK7 (solid gray bar) in serous and papillary serous carcinomas from each tumor stage (I, II, III,
and IV) was analyzed by qRT-PCR, and the mean fold changes were calculated by normalizing against expression in normal epithelial ovary tissues
(N). The number of samples used in the analyses is denoted in parentheses, and standard error bars are indicated. (B) Specific protein expression
analyzed in immune-blots of pooled normal (N) donor sera (n = 11) and various subtypes (serous and papillary serous only is indicated by an
asterisk) from OVC patients of multiple stages (I, II, III, and IV). All serum samples were pre-cleared to deplete the 12 most abundant serum
proteins prior to electrophoresis (SDS-PAGE). KLK protein expression in each sample was normalized relative to the internal transferrin signal.
The histograms in the graphs adjacent to the immune-blots display the fold changes in KLK protein expression levels, normalized against
pooled normal (N) serum and transferrin, as measured by quantitative densitometry.

expression detected by qRT-PCR, these mRNAs were
up-regulated only 2.3-fold over the control when analyzed
by microarray (data not shown), and this result may perhaps be due to the limitation of the physical kinetics of
oligonucleotide probe-to-oligonucleotide substrate binding

seen with chip-based detection methods. The validation of
KLK6 and KLK7 overexpression, specifically in OVC versus other major human cancer types, again indicates that
the pre-screening methods used may be highly effective for
identifying candidate biomarkers.
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Figure 6 CA-125 and HE4 levels were both increased in only 58% of serum samples of early stage serous carcinoma patients as
measured by ELISA. CA-125 (A) and HE4 (B) production was measured by ELISA. Levels of these proteins were calculated as averages of triplicates.
The line across the figures is the low threshold for protein up-regulation. An asterisk (*) indicates that this particular patient demonstrated no up-regulation
in both CA-125 and HE4.

The KLK serine proteases are known to be involved in
several cancer types, and cancer-specific expression profiles suggest their diagnostic and prognostic values [25].
The KLK6 protein is normally expressed as a pro-enzyme
in multiple tissues in adults, and is activated by cleavage
by other proteases whereupon it is secreted into biological
fluids [55,56]. Mature KLK6 degrades basic constituents
of the extracellular matrix and basement membrane in
tissues [57]. In advanced OVCs, overexpression of these
proteases by transfection was directly associated with
shorter disease-free survival and overall survival [58]. In
addition, KLK6 overexpression in ovarian cell lines leads
to transformation to a malignant cell phenotype [58], and
together with osteopontin in the form of free antigens, has
been associated with high grade ovarian tumors [59]. The
combination of KLK6 and KLK13 overexpression is associated with tumor recurrence [60]. Similarly, KLK7, also
known as stratum corneum chymotryptic enzyme, is also
over-expressed in human cancers and is secreted into

bodily fluids [61,62]. KLK7 overexpression in ovarian carcinoma cells results in the formation of multicellular aggregates and promotes chemo-resistance [63]. However, in
contrast to previous studies, in a recent study, multivariate
analyses of KLK7 levels determined by immunohistochemistry and ELISA of tumor tissue extracts demonstrated that these levels were significantly correlated with
both overall survival and disease free survival [64].
The much higher expression of KLK6 and KLK7 genes
in ovarian carcinomas versus normal ovarian tissues
(largely stroma elements and germline-derived) suggests
that basal expression is low and may be tightly regulated
in the epithelium by the presence of hormones and other
factors in normal ovaries. A high proliferation rate of ovarian tumor epithelial elements compared to stroma elements during cancer progression would make KLK6 and
KLK7 an excellent set of early detection biomarkers because they are significantly overexpressed to levels above
that of normal controls in the majority of ovarian tumor
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subtypes in early stages. Our immune-histologic analysis
of normal ovarian tissues demonstrated that these two
proteins were exclusively located on the epithelium surface of normal ovarian tissues but not in the neighboring
stroma, and the remarkable increase in mRNA and protein expression was directly associated with an expansion
of tumor cells in the tumor epithelial compartment as opposed to a normal ovary, which is largely composed of
stroma. This signature may be related to the secretion of
cytokines, growth factors and steroids as well as the expression of hormone receptors on the ovarian surface epithelium in epithelial OVCs [65]. Similarly, KLKs are more
enzymatically active and expressed at higher levels around
the ovulation period when the ovaries are stimulated by
gonadotrophin [66], suggesting that steroid hormones may
play a major role in KLK regulation. Steroid hormonerelated signaling has also been found in other cancer types
[67-69], and the up-regulation of KLK6 and KLK7 in OVC
may thus involve additional cofactors or unique properties
of hormonal surges to explain the specificity of the
observed overexpression.
In relation to the clinicopathology of tumor progression, maintaining the overexpression of these two proteins has strong implications in metastasis since they
enzymatically target several major extracellular proteins
such as fibronectin and laminin, as well as other structural
proteins related to myelin basic protein, gelatin and casein
[70]. The known activity of KLK7 in the desquamation of
cornified layers in normal skin may be very similar to its
role in metastasis [71].
Typically, the majority of common epithelial ovarian
carcinomas will reach malignancy [72], and our data
consistently indicate that KLK6 and KLK7 mRNA and
protein are progressively overexpressed as tumors advanced to malignancy. As opposed to KLK levels in OVC
tissue, KLK levels in serum, when measured by immuneblotting, reach a peak at stage I and then decrease in
stages III and IV to low basal levels. While the mechanisms underlying this decrease in serum protein levels are
not clearly understood, they may involve either a blockade
of secretion pathways or loss of epitopes by enhanced proteolysis of KLK. A relevant example for the latter effect is
the decline in KLK3 (also known as prostate-specific antigen (PSA)) levels in serum due to enhanced proteolysis
that accompanies disease progression [73].
As described previously, CA-125 and HE4 have been
commonly used in the clinic as OVC biomarkers. However, it should be noted that although both were approved by the FDA as OVC biomarkers, they are mainly
used for disease monitoring. Nonetheless, in the absence
of other biomarkers, they are often used as early detection tools or as a part of combined biomarkers kits such
as ROMA and OVA1 [74]. Our measurements of these
proteins in early stage patients indicated that in 7 out of
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19 early stage patients, both CA-125 and HE4 were
below normal levels, and therefore did not complement each other efficiently for early detection purposes. Although our population of early stage patients
was relatively small (N =19), our results are consistent
with larger studies that indicated low sensitivity, mostly
for CA-125 and the inability of combined CA-125 and
HE4 tests to detect the disease for a large range of ovarian
carcinoma subtypes [15]. In addition, we compared serum
expression of CA-125 and HE4 as measured by ELISA
assays to the production of KLK6 and KLK7 in the
same patients as measured by immune-blot analysis.
Immunoblotting may be more sensitive than ELISA,
and these differences in sensitivity may account for the
different results. However, the finding that 3 out of 4
patients (stage III and IV) demonstrated increased
levels of both CA-125 and HE4 may indicate that the
ELISA assays do have sufficient sensitivity. In addition,
one required characteristic of potential biomarkers is
the ease of detection in routine tests. Therefore, we
have made progress in our laboratory in developing
specific ELISA tests that will be able to efficiently measure
levels of these proteins in serum samples. Our preliminary
ELISA data in larger populations of early stage OVC
patients, benign patients and healthy individuals demonstrated up-regulation, mostly of KLK7, in early stage
patients. These data were obtained using commercial
ELISA kits or anti-KLK antibodies that have been developed in our lab (data not shown). Since KLK6 is aberrantly glycosylated and is subject to heterogeneity [75,76],
we recognize the need to develop a specialized ELISA for
this protein that will account for potential post-translation
modifications and allow accurate identification of its levels
in blood serum.
Lastly, we purpose that KLKs may improve diagnostic
specificity of OVC. CA125 tends to increase above normal
levels in many benign conditions mostly in premenopausal
women. Although it demonstrates better specificity than
CA125, HE4 has not been approved to be used as an early
detection biomarker on its own. Our analysis of KLK6 and
KLK7 presence in normal, benign and OVC patients indicated their significant increase in OVC compared to the
benign group. In addition, preliminary AUC/ROC analysis
demonstrated relatively high values for KLK7 in the OVC
group (0.83 against normal and 0.73 against the benign
group). Therefore, KLK7 and possibly KLK6 may help address the concern of over-diagnosis of OVC when used together with other established biomarkers.

Conclusions
Given the high mortality rate of OVC in later stages
[77], and the lack of reliable biomarkers for detection of
early stage OVC, this study focused on determining
whether KLK6 and KLK7 can be used as potential early
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detection biomarkers. Serous and papillary serous are
major epithelial ovarian carcinoma subtypes, and more
than 50% will reach malignancy [72]. The key findings of
our study readily address the challenge for robust biomarkers that will enable early detection of OVC in the
clinic. The observations that KLK6 and KLK7 mRNA
and protein levels are highly elevated in OVC tissue and
serum in early stage OVCs may provide important tools
for diagnosis of these diseases. Therefore, detection of
higher levels of KLKs in early stage OVC patients can
help in making a definitive diagnosis if diagnostic laparoscopy, a minimally-invasive procedure that is safer and
simpler than diagnostic laparotomy, was found to be
positive. Since we demonstrated that KLK6 and KLK7
are expressed in tissue as well as in serum of early-stage
OVC, detecting these proteins in tissue samples obtained
through diagnostic laparoscopy can significantly complement the diagnostic power of this surgical procedure.
One of our main goals was to effectively compare the
production of KLK6 and KLK7 to more commonly used
biomarkers such as CA-125 and HE4. In order to further
develop KLK6 and KLK7 as possibly more sensitive detection tools for routine clinical use, it will eventually be critical to explore a multiplex assay platform that would enable
the simultaneous measurement of multiple biomarkers in
blood. Such tools for early diagnosis will likely contribute
to reducing the mortality rate of OVC.
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ANOVA: Analysis of variance; DAB: Diaminobenzidine; PFA: Paraformaldehyde;
DIG: Digoxigenin; BSA: Bovine serum albumin; SDS-PAGE: Sodium dodecyl
sulfate-containing polyacrylamide gels; PMSF: P-methylsulfonylfluoride;
HRP: Horse radish peroxidase; ELISA: Enzyme-linked immuno-sorbent assay.
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